AI Article Synopsis

  • A study aimed to explore the link between cannabis use and chronic kidney disease (CKD) through both retrospective cohort analysis and Mendelian randomization using a large dataset.
  • The research found that while infrequent cannabis users did not show increased CKD risk, those who used cannabis weekly or daily had a significant association with higher CKD odds.
  • However, genetic predisposition to cannabis use disorder did not correlate with increased CKD risk, indicating that the relationship may not be causal.

Article Abstract

Rationale & Objective: The association between cannabis use and chronic kidney disease (CKD) is controversial. We aimed to assess association of CKD with cannabis use in a large cohort study and then assess causality using Mendelian randomization with a genome-wide association study (GWAS).

Study Design: Retrospective cohort study and genome-wide association study.

Setting & Participants: The retrospective study was conducted on the All of Us cohort (N=223,354). Genetic instruments for cannabis use disorder were identified from 3 GWAS: the Psychiatric Genomics Consortium Substance Use Disorders, iPSYCH, and deCODE (N=384,032). Association between genetic instruments and CKD was investigated in the CKDGen GWAS (N > 1.2 million).

Exposure: Cannabis consumption.

Outcomes: CKD outcomes included: cystatin-C and creatinine-based kidney function, proteinuria, and blood urea nitrogen.

Analytical Approach: We conducted association analyses to test for frequency of cannabis use and CKD. To evaluate causality, we performed a 2-sample Mendelian randomization.

Results: In the retrospective study, compared to former users, less than monthly (OR, 1.01; 95% CI, 0.87-1.18;  = 0.87) and monthly cannabis users (OR, 1.15; 95% CI, 0.86-1.52;  = 0.33) did not have higher CKD odds. Conversely, weekly (OR, 1.28; 95% CI, 1.01-1.60;  = 0.04) and daily use (OR, 1.25; 95% CI, 1.04-1.50;  = 0.02) was significantly associated with CKD, adjusted for multiple confounders. In Mendelian randomization, genetic liability to cannabis use disorder was not associated with increased odds for CKD (OR, 1.00; 95% CI, 0.99-1.01;  = 0.96). These results were robust across different Mendelian randomization techniques and multiple kidney traits.

Limitations: Likely underreporting of cannabis use. In Mendelian randomization, genetic instruments were identified in the GWAS that included individuals primarily of European ancestry.

Conclusions: Despite the epidemiological association between cannabis use and CKD, there was no evidence of a causal effect, indicating confounding in observational studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879977PMC
http://dx.doi.org/10.1016/j.xkme.2022.100582DOI Listing

Publication Analysis

Top Keywords

mendelian randomization
20
cannabis ckd
12
genetic instruments
12
cannabis
10
ckd
9
association cannabis
8
cohort study
8
genome-wide association
8
retrospective study
8
cannabis disorder
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!